Updated:
Human Longevity and Performance Impact Venture Fund
Wei-Wu He's longevity-focused venture fund uses proprietary genomic data from Human Longevity, Inc. to invest in early-stage health-tech.
Human Longevity and Performance Impact Venture Fund
The most comprehensive executive health assessment — full-body MRI, whole genome sequencing, 120+ biomarkers & AI analysis in one visit. Starting at $8,000.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Wei-Wu He
Founder and General Partner
Sector focus
Frequently asked questions
How does the fund's connection to Human Longevity, Inc. affect its investment process?
The fund draws on the genomic and phenotypic database generated by Human Longevity, Inc.'s Health Nucleus facility. This provides a proprietary clinical-data layer that can validate a portfolio company's biomarker claims or biological-age measurement tools before investment. The relationship effectively gives the fund a captive beta site and a diligence resource that independent VC firms do not possess.
Who runs investment decisions at the Human Longevity and Performance Impact Venture Fund?
Wei-Wu He is the Founder and General Partner. He also serves as Executive Chairman of Human Longevity, Inc. and is the founder of Emerging Technology Partners, a venture firm that frequently co-invests with the fund. No other investment committee members have been publicly identified.
Does the fund participate in fund commitments or only direct deals?
Available public information suggests the fund operates primarily through direct, early-stage equity investments and co-investments alongside partners such as Emerging Technology Partners and BOLD Capital Partners. There is no public record of this vehicle participating as an LP in third-party venture funds.
What is the fund's known posture on co-investments alongside external GPs?
The fund actively co-invests with a tight circle of longevity-focused venture firms. Named co-investors include BOLD Capital Partners, led by Peter Diamandis, and the Longevity Vision Fund, led by Sergey Young. The fund's ties to Emerging Technology Partners, Wei-Wu He's other venture firm, mean many deals are likely structured as joint investments.
Where does the underlying wealth for this fund come from?
The precise wealth origin and fund size have not been publicly disclosed. The fund is sponsored by Human Longevity, Inc., the genomics company co-founded by Wei-Wu He, J. Craig Venter, and Peter Diamandis. It appears to be a corporate venture-style vehicle rather than a family office or a fund backed by external institutional LPs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: